[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100558984":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":13,"armGroups":20,"interventions":37,"overallOfficials":59,"centralContacts":63,"locations":69,"responsibleParty":86,"collaborators":13,"id":88,"slug":13,"hasResults":89,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":13,"eligibilityCriteria":93,"healthyVolunteers":89,"sex":94,"minAge":95,"maxAge":96,"enrollmentInfo":97,"targetDuration":13,"studyType":100,"phases":101,"briefSummary":103,"conditions":104,"keywords":13,"overallStatus":72,"whyStopped":13,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},{"fullName":5,"class":6},"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"progression free survival，PFS","defined as the time from receiving treatment until disease progression or death from any cause, whichever happens first.","through study completion, up to 2 year",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":19,"maskingDescription":13,"whoMasked":13},"NONE",[21,28,32],{"label":22,"type":23,"description":24,"interventionNames":25},"Group A","EXPERIMENTAL","ZG005 10 mg\u002Fkg administered intravenously every 3 weeks (Q3w) + Bevacizumab (Avastin®) 15 mg\u002Fkg administered intravenously Q3w",[26,27],"Biological: ZG005 for Injection","Biological: Bevacizumab",{"label":29,"type":23,"description":30,"interventionNames":31},"Group B","ZG005 20 mg\u002Fkg administered intravenously Q3w + Bevacizumab (Avastin®) 15 mg\u002Fkg administered intravenously Q3w",[26,27],{"label":33,"type":23,"description":34,"interventionNames":35},"Group C","Sintilimab 200 mg administered intravenously Q3w + Bevacizumab (达攸同®) 15 mg\u002Fkg administered intravenously Q3w",[36,27],"Biological: Sintilimab",[38,45,51,55],{"type":39,"name":40,"description":41,"armGroupLabels":42,"otherNames":43},"BIOLOGICAL","ZG005 for Injection","10 mg\u002Fkg or 20 mg\u002Fkg administered intravenously Q3w",[22,29],[44],"ZG005",{"type":39,"name":46,"description":47,"armGroupLabels":48,"otherNames":49},"Bevacizumab","15 mg\u002Fkg administered intravenously Q3w",[22,29],[50],"Avastin",{"type":39,"name":52,"description":53,"armGroupLabels":54,"otherNames":13},"Sintilimab","200 mg administered intravenously Q3w",[33],{"type":39,"name":46,"description":47,"armGroupLabels":56,"otherNames":57},[33],[58],"达攸同",[60],{"name":61,"affiliation":5,"role":62},"Jason Wu","STUDY_CHAIR",[64],{"name":65,"role":66,"phone":67,"phoneExt":13,"email":68},"Bo Liu","CONTACT","+86-021-5838-2983","liub@zelgen.com",[70],{"facility":71,"status":72,"city":73,"state":74,"zip":13,"country":75,"countryCode":76,"cosmosGeoPoint":77,"geoPoint":82,"contacts":83},"West China Hospital of Sichuan University","RECRUITING","Chengdu","Sichuan","China","CN",{"type":78,"coordinates":79},"Point",[80,81],104.06667,30.66667,{"lat":81,"lon":80},[84],{"name":85,"role":66,"phone":13,"phoneExt":13,"email":13},"Hong Wu",{"type":87,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR","100558984",false,"NCT06558227","Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma","A Multicenter, Randomized, Open-label Phase II Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab for First-line Treatment of Advanced Hepatocellular Carcinoma","Inclusion Criteria:\n\n* Fully understand the study and voluntarily sign the informed consent form.\n* 18-75 years of age;\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1；\n* Life expectancy ≥ 12 weeks.\n\nExclusion Criteria:\n\n* Patients were deemed unsuitable for participating in the study by the investigator for any reasons.","ALL","18 Years","75 Years",{"count":98,"type":99},90,"ESTIMATED","INTERVENTIONAL",[102],"PHASE2","This study is a randomized, open-label, positive-controlled, multicenter phase II clinical trial. It evaluates the efficacy and safety of ZG005 combined with Bevacizumab compared to Sintilimab combined with Bevacizumab in first-line treatment for patients with advanced hepatocellular carcinoma.",[105],"Hepatocellular Carcinoma","2024-12-11",{"date":108,"type":109},"2024-12-16","ACTUAL",{"date":111,"type":109},"2024-10-24",{"date":113,"type":99},"2026-10",{"name":5,"class":6},1]